tirzepatide surmount 3 SURMOUNT-5: shows superior weight loss over semaglutide Tirzepatide after Intensive Lifestyle Intervention

GLP-1 Market for Tirzepatide, till 2035 13.2.8

Semaglutide Gets More Popular for Weight Management Semaglutide's popularity for weight loss is growing due to its effectiveness

Semaglutide (Wegovy, Ozempic) Half-life: ~7 days Dosing: Once weekly subcutaneous injection Profile: Provides steady appetite suppression and glycemic control

The Tirzepatide Discontinuation Evidence Gap Obesity medicine currently lacks prospective, randomized trials comparing structured taper protocols to abrupt discontinuation for any GLP-1 receptor agonist

Modest increases (4059%) were achieved using the dose of 300 mg/d approved by the FDA and EFSA, with larger increases (more than a doubling of the sample mean or doubling of concentration in the highest responder) requiring doses far in excess (10002000 mg/d)